GR3031208T3 - Attenuated respiratory syncytial virus vaccine compositions. - Google Patents

Attenuated respiratory syncytial virus vaccine compositions.

Info

Publication number
GR3031208T3
GR3031208T3 GR990402303T GR990402303T GR3031208T3 GR 3031208 T3 GR3031208 T3 GR 3031208T3 GR 990402303 T GR990402303 T GR 990402303T GR 990402303 T GR990402303 T GR 990402303T GR 3031208 T3 GR3031208 T3 GR 3031208T3
Authority
GR
Greece
Prior art keywords
attenuated
virus
respiratory syncytial
syncytial virus
vaccine compositions
Prior art date
Application number
GR990402303T
Other languages
English (en)
Inventor
Brian Robert Murphy
Robert Merritt Chanock
James Earl Crowe Jr
Mark Connors
Kuo-Hom Lee Hsu
Alan Robert Davis
Michael David Lubeck
Bernard Hugh Selling
Original Assignee
American Home Prod
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod, Us Health filed Critical American Home Prod
Publication of GR3031208T3 publication Critical patent/GR3031208T3/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Vertical, Hearth, Or Arc Furnaces (AREA)
GR990402303T 1992-04-21 1999-09-15 Attenuated respiratory syncytial virus vaccine compositions. GR3031208T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87274692A 1992-04-21 1992-04-21
US3994593A 1993-04-09 1993-04-09
PCT/US1993/003670 WO1993021310A1 (en) 1992-04-21 1993-04-20 Attenuated respiratory syncytial virus vaccine compositions

Publications (1)

Publication Number Publication Date
GR3031208T3 true GR3031208T3 (en) 1999-12-31

Family

ID=26716607

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990402303T GR3031208T3 (en) 1992-04-21 1999-09-15 Attenuated respiratory syncytial virus vaccine compositions.

Country Status (18)

Country Link
US (3) US5922326A (el)
EP (1) EP0640128B1 (el)
JP (1) JP3883202B2 (el)
KR (1) KR100257171B1 (el)
AT (1) ATE181359T1 (el)
AU (1) AU683840B2 (el)
CA (1) CA2118509C (el)
DE (1) DE69325370T2 (el)
DK (1) DK0640128T3 (el)
ES (1) ES2132233T3 (el)
GR (1) GR3031208T3 (el)
HU (1) HU220189B (el)
IL (1) IL105456A (el)
MX (1) MX9302278A (el)
NZ (1) NZ252857A (el)
RU (1) RU2139729C1 (el)
UA (1) UA41315C2 (el)
WO (1) WO1993021310A1 (el)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
TW275632B (el) * 1992-04-21 1996-05-11 American Cyanamid Co
AU677090B2 (en) 1993-08-06 1997-04-10 Connaught Laboratories Limited Inactivated respiratory syncytial viral vaccines
US7223410B1 (en) 1994-08-05 2007-05-29 Sanofi Pasteur Limited Inactivated respiratory syncytial viral vaccines
WO1996010400A1 (en) * 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6083925A (en) * 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US20050287540A1 (en) * 1995-09-27 2005-12-29 Murphy Brian R Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
EP0917592A4 (en) * 1996-04-04 2002-04-24 Univ Michigan REDUCED RSV
US6077514A (en) * 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
CA2260107A1 (en) * 1996-07-12 1998-01-22 The Regents Of The University Of Michigan Two-step immunization procedure against the pyramyxoviridae family of viruses using attenuated viral strains and subunit protein preparation
KR100658491B1 (ko) 1996-07-15 2006-12-18 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클론닝된 뉴클레오타이드 서열로부터 약독화된 호흡기 세포 융합 바이러스 백신의 생산
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
CN1232504A (zh) * 1996-09-27 1999-10-20 美国氰胺公司 在单链负义病毒目病毒内引起减毒的3'基因组启动子区和聚合酶基因中的突变
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
FR2764903A1 (fr) * 1997-06-23 1998-12-24 Pasteur Institut Detection des infections par des paramyxovirus (virus respiratoire syncitial et virus parainfluenza) utilisant des polynucleotides codant de la proteine l
US7662397B2 (en) 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US6579528B1 (en) 1998-08-13 2003-06-17 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6482414B1 (en) 1998-08-13 2002-11-19 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
EP1690940A1 (en) 1999-04-13 2006-08-16 The Government of the United States of America as Represented by The Department of Health and Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
BR0013195A (pt) * 1999-07-09 2002-07-23 Government Of The Us Dept Of H Produção de vacinas de virus sincicial respiratório quimérico humano-bovino, atenuado
US7820182B2 (en) * 1999-07-09 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
JP2003528925A (ja) 2000-04-03 2003-09-30 ザ ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エドゥケーション 低温適応型ウマインフルエンザウイルス
US7118888B2 (en) * 2001-09-28 2006-10-10 University Of South Florida Board Of Trustees Gene expression vaccine
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
JP2005523698A (ja) 2002-04-26 2005-08-11 メディミューン・ヴァクシンズ・インコーポレーテッド インフルエンザウイルスの生産用多重プラスミドシステム
WO2004028478A2 (en) * 2002-09-27 2004-04-08 Medimmune Vaccines, Inc. Functional mutations in respiratory syncytial virus
WO2004083397A2 (en) * 2003-03-18 2004-09-30 Wyeth Holdings Corporation Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv
ATE469170T1 (de) * 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
CA2816222A1 (en) * 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
EP1697521B1 (en) 2003-12-23 2010-06-02 MedImmune, LLC Multi plasmid system for the production of influenza virus
ES2454266T3 (es) * 2004-05-25 2014-04-10 Medimmune, Llc Variantes de la hemaglutinina y la neuraminidasa de influenza
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
WO2008133701A1 (en) * 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
CN101983069B (zh) 2006-08-09 2014-07-16 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
JP5666905B2 (ja) * 2007-06-18 2015-02-12 メディミューン,エルエルシー ヘマグルチニンポリペプチド中に変化を有するインフルエンザbウイルス
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
AU2009268576B2 (en) * 2008-07-11 2014-03-27 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
CN102361649A (zh) 2009-02-12 2012-02-22 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
GB201003630D0 (en) 2010-03-04 2010-04-21 Novartis Ag Avian rotavirus
EP2764015A1 (en) 2011-10-07 2014-08-13 Medlmmune, LLC Influenza hemagglutinin variants
PL3511015T3 (pl) 2012-04-13 2021-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetycznie stabilna żywa atenuowana szczepionka przeciw syncytialnemu wirusowi oddechowemu i jej wytwarzanie
AU2014236340B2 (en) 2013-03-14 2019-01-17 Massachusetts Institute Of Technology Nanoparticle-based compositions
WO2014152534A1 (en) 2013-03-14 2014-09-25 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
JP7311872B2 (ja) 2015-10-29 2023-07-20 エモリー ユニバーシティー キメラrsv、免疫原性組成物、及び使用方法
RU2746280C1 (ru) * 2020-08-03 2021-04-12 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) Штамм респираторно-синцитиального вируса RSV/Novosibirsk/66Hl/2018 для использования в диагностике респираторно-синцитиальной вирусной инфекции и исследования эффективности противовирусных препаратов in vitro

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
US5250298A (en) * 1988-10-07 1993-10-05 University Of Delaware Live attenuated newcastle disease virus vaccines and preparation thereof

Also Published As

Publication number Publication date
EP0640128A1 (en) 1995-03-01
HUT69992A (en) 1995-09-28
NZ252857A (en) 1997-06-24
IL105456A (en) 1996-12-05
RU94045898A (ru) 1996-09-20
MX9302278A (es) 1994-07-29
KR100257171B1 (ko) 2000-05-15
US5882651A (en) 1999-03-16
WO1993021310A1 (en) 1993-10-28
EP0640128B1 (en) 1999-06-16
AU4290793A (en) 1993-11-18
KR950701382A (ko) 1995-03-23
US5922326A (en) 1999-07-13
ATE181359T1 (de) 1999-07-15
DE69325370T2 (de) 1999-10-14
CA2118509C (en) 2009-05-19
DK0640128T3 (da) 1999-11-22
UA41315C2 (uk) 2001-09-17
IL105456A0 (en) 1993-08-18
RU2139729C1 (ru) 1999-10-20
DE69325370D1 (de) 1999-07-22
ES2132233T3 (es) 1999-08-16
JPH07505891A (ja) 1995-06-29
JP3883202B2 (ja) 2007-02-21
AU683840B2 (en) 1997-11-27
US6284254B1 (en) 2001-09-04
HU9403023D0 (en) 1994-12-28
HU220189B (hu) 2001-11-28
CA2118509A1 (en) 1993-10-28

Similar Documents

Publication Publication Date Title
GR3031208T3 (en) Attenuated respiratory syncytial virus vaccine compositions.
BRPI9710363B8 (pt) partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso.
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
CA2339089A1 (en) Cold-adapted equine influenza viruses
TW266228B (el)
WO1996013512A3 (en) L-ribofuranosyl nucleosides
PL340659A1 (en) Spheroides, method of obtaining them and pharmacological compositions
PL332694A1 (en) Purine l-nucleosides, their analoques and their application
AU1198697A (en) Stabilizers for live vaccines
EE200200507A (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
GB9306731D0 (en) Vaccines
NZ504894A (en) Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique
MD1838G2 (ro) Derivaţi de 5,6-diclorbenzimidazol, procedeu de obţinere a lor, compoziţie farmaceutică şi metodă de tratament sau de prevenire a infecţiei virotice herpetice
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
WO2000057908A3 (en) Attenuated dengue-1 virus vaccine
WO2000057904A3 (en) Attenuated dengue-3 virus vaccine
MXPA02007403A (es) Derivados de pirrol, sustituidos con 4-piridilo y 2,4-pirimidinilo, y su uso en farmacia.
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
WO2001034184A3 (en) Methods and compositions for protection against bovine herpesvirus 1
CA2222482A1 (en) Non-virulent mycoplasma synoviae and vaccine thereof
CA2122604A1 (en) Uses of aloe products, e.g. acemannan, in the treatment of diseases requiring intervention of the immune system for cure
WO2003006645A3 (en) Method and composition for inhibiting heparanase activity
UA10302A (uk) Спосіб лікуваhhя чоловічого гіпогоhадизму
IT1265303B1 (it) Derivati metallorganici degli acidi s-acil-2-(s)-(2-pirrolidon-5-(s)- carbonilamido)-3-mercapto propionici con zinco, procedimento per la